ObvioHealth
, a global medical technology company, announces the launch of its mobile application for site-less clinical studies-ClaimIt. ClaimIt removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, lowering drop-out rates and accelerating data capture – all of which help reduce exorbitant costs for study sponsors and create opportunities to leverage the data capture from connected devices for clinical evaluation. “For decades, the clinical research industry has followed an archaic model, but now there’s a better option,” said Bryan Silverman, CEO of ObvioHealth. “Our mobile model challenges the industry to put patients first. ClaimIt allows study subjects to take part in important healthcare research from the comfort of their homes.” ClaimIt maintains best-in-class clinical standards and compliance in studies ranging from pharmaceutical and nutrition, to observational and more. ObvioHealth’s clinical professionals and medical doctors monitor each study while study participants use the ClaimIt app on their smart phones or tablets, recording study specific information and allowing for real-time data collection. Study protocols can be designed with smart devices, such as a Bluetooth blood pressure monitor, and the data from such devices immediately integrates with the ClaimIt app – providing real-world evidence. ClaimIt also offers real-time, 24/7 data monitoring, meaning adverse events are detected immediately. Healthcare professionals can video chat or text with participants at any time. ObvioHealth is financially backed by TKS1, a venture capital collaboration between SPRIM, a life sciences consulting agency with deep experience as a clinical research organization, and Tikehau Capital (TKO.FP), an alternative asset management and investment company. In March, ObvioHealth received a Series A investment. “ClaimIt will help advance the latest treatments in healthcare, which is why we invested so confidently in ObvioHealth,” said Bruno de Pampelonne, CEO of Tikehau IM. “We’re happy to see the technology come to fruition and believe its transformation of the industry is just getting started.” Find more information on ClaimIt, visit ObvioHealth’s official site
here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.